QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.

Press

27May 2025

🔍 How will access to new orphan drugs look like in the future?

Quantify Research‘s own Konstantin Macheridis shares insights in a newly published article on access to treatments for rare diseases. The Swedish HTA-agency Tandvårds- och läkemedelsförmånsverket, TLV has undertaken development work to increase access to orphan drugs through the national reimbursement system. The hope is that it will lead to improved access to orphan drugs – […]

23May 2025

Quantify Finland at the HTA Medications 2025 Event

This week, experts from the Quantify Research Finland group took part in HTA of Medications 2025, hosted by Pharmaca.

It was a day full of rich discussions and valuable insights with top HTA professionals from government and industry.

The perspectives we gained are already feeding into our Market Access & Strategy work, helping us better support our clients navigating the evolving HTA landscape in Finland.

Here […]

21May 2025

Quantify warmly welcomes Laura to the team!

We are excited to welcome Laura Tølløse to the Quantify Research team, expanding our capabilities in Denmark!

🧠 Laura has a Master of Science in Public Health from the University of Copenhagen (Københavns Universitet), where she utilised Danish registry data to investigate the impact of an educational interventions among preventive home visitors on several health outcomes among elderly receiving the home visits.

👩‍💻 In […]

21May 2025

How do we assess the value of medicines – and what´s next for HTA in Finland?

Quantify Research‘s Finnish team is excited to take part in Pharma Academy’s event on Health Technology Assessment (HTA) on May 21st, 2025!

This event will explore how we assess the therapeutic and economic value of treatments, how real-world data supports decision-making, and how HTA is evolving in both national and international contexts.

🔍 Key discussions points:
🟢 HTA’s role in access and reimbursement decisions
🟢 Using real-world […]